Loading AI tools
Chemical compound From Wikipedia, the free encyclopedia
Glycopyrronium bromide is a medication of the muscarinic anticholinergic group.[7] It does not cross the blood–brain barrier and consequently has few to no central effects. It is given by mouth,[8] via intravenous injection, on the skin,[9] and via inhalation.[4][5][6] It is a synthetic quaternary ammonium compound.[2] The cation, which is the active moiety, is called glycopyrronium (INN)[10] or glycopyrrolate (USAN).
Clinical data | |
---|---|
Trade names | Robinul, Cuvposa, Seebri, others |
Other names | glycopyrrolate (USAN US) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a602014 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth, intravenous, inhalation, topical, injection, subcutaneous |
Drug class | Antimuscarinic agent |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 0.6–1.2 hours |
Excretion | 85% Kidney, unknown amount in the bile |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI | |
ChEMBL |
|
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.008.990 |
Chemical and physical data | |
Formula | C19H28BrNO3 |
Molar mass | 398.341 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
The most common side effects include irritability, flushing, blocked nose, reduced secretions in the airways, dry mouth, constipation, diarrhea, vomiting and inability to completely empty the bladder (urinary retention).[7]
In September 2012, glycopyrronium was approved for medical use in the European Union.[4] In June 2018, glycopyrronium was approved by the US Food and Drug Administration (FDA) to treat excessive underarm sweating, becoming the first drug developed specifically to reduce excessive sweating.[11] It is on the World Health Organization's List of Essential Medicines.[12]
Glycopyrronium was first used in 1961 to treat peptic ulcers. Since 1975, intravenous glycopyrronium has been used before surgery to reduce salivary, tracheobronchial, and pharyngeal secretions.[13] It is also used in conjunction with neostigmine, a neuromuscular blocking reversal agent, to prevent neostigmine's muscarinic effects such as bradycardia.[14] It can be administered to raise the heart rate in reflex bradycardia as a result of a vasovagal reaction, which often will also increase the blood pressure.[15]
It is also used to reduce excessive saliva (sialorrhea),[7][16][17][18] and to treat Ménière's disease.[19]
It has been used topically and orally to treat hyperhidrosis, in particular, gustatory hyperhidrosis.[20][21]
In inhalable form it is used to treat chronic obstructive pulmonary disease (COPD).[4][5][6] Doses for inhalation are much lower than oral ones, so that swallowing a dose will not have an effect.[22][23]
Dry mouth, urinary retention, headaches, vomiting, diarrhea, constipation, blurry vision are possible side effects of the medication.[13]
Glycopyrronium competitively blocks muscarinic receptors,[13][24] thus inhibiting cholinergic transmission.
Glycopyrronium bromide affects the gastrointestinal tracts, liver and kidney but has a very limited effect on the brain and the central nervous system. In horse studies, after a single intravenous infusion, the observed tendencies of glycopyrronium followed a tri-exponential equation, by rapid disappearance from the blood followed by a prolonged terminal phase. Excretion was mainly in urine and in the form of an unchanged drug. Glycopyrronium has a relatively slow diffusion rate, and in a standard comparison to atropine, is more resistant to penetration through the blood-brain barrier and placenta.[25]
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.